|
WO2021009950A1
|
|
Agent for enhancing effect of anticancer agent
|
|
JP2020176071A
|
|
Novel method and agent for treatment of blood cancer
|
|
WO2019142490A1
|
|
Urine alkali agent useful for treatment of cancer patient
|
|
KR20190046937A
|
|
A pharmaceutical composition for treating or remedying chronic myelogenous leukemia
|
|
WO2019016928A1
|
|
New anti-malignant tumor agent based on specificity of cancer cell metabolism
|
|
CN107001617A
|
|
New PEG derivatives
|
|
RU2689557C2
|
|
Using pharmaceutical composition for treating or creating remission conditions in elderly patient with solid cancer
|
|
JP2015091765A
|
|
Anticancer agent having no adverse effect
|
|
KR20150118955A
|
|
Locally administered liposome and application therefor
|
|
CN103561775A
|
|
Liposome containing shRNA molecule for thymidylate synthase, and use for same
|
|
AU2010312594A1
|
|
Novel 5-fluorouracil derivative
|
|
US2012029182A1
|
|
Stable crystal of 1-(2′-cyano-2′-deoxy-β-D-arabinofuranosyl)cytosine monohydrochloride
|
